A group from the Cancer Research Centre (CIC, CSIC-USAL-FICUS) has found that the drug tacrolimus, an immunosuppressant commonly used to prevent organ transplant rejection, manages to halt the progression of peripheral T-cell lymphomas in mouse models using only 25 percent of the standard immunosuppressive dose.
These peripheral T-cell lymphomas, tumors of the immune system with a poor prognosis and few treatment alternatives, have been analyzed in depth by the team, which has published its findings in "Nature Communications". In the work they have also clarified how mutations with effects that appear to be opposite in the RHOA gene are capable of driving the appearance of these lymphomas. The data indicate that both types of alterations confer on the RHOA protein a novel function that favors tumor development.
The origin of the tumors usually requires combinations of genetic changes in different genes, which end up persistently activating or silencing certain functions in malignant cells. What is unusual, the authors highlight, is that mutations that increase or reduce the activity of the same gene can nevertheless promote the same cancer subtype, as happens with RHOA in peripheral T-cell lymphomas.
Alterations in RHOA are frequent in some of these lymphomas. Specifically, they are detected in close to 70 percent of nodal lymphomas of follicular T-cells, a subtype that arises in lymph nodes from specialized T lymphocytes that collaborate in the production of antibodies.
"Both mutations that enhance the functions of RHOA and others that inhibit them provide this protein with a completely new function that favors the malignancy of T lymphocytes and the subsequent development of lymphomas," explains Xosé R. Bustelo, a researcher at the CIC, at CIBERONC, and director of the study.
Under normal conditions, the RHOA protein acts as a molecular switch that alternates between active and inactive states. In these lymphomas, some mutations increase its function and others block it, but despite their opposing effects, both ultimately drive the same tumor process.
The key lies in an additional function, called neomorphic activity, which allows both types of mutations to activate a common oncogenic pathway. "The key was not whether RHOA was more or less active, but that the mutations give it a new function, which makes it possible to understand how seemingly opposite alterations can favor these lymphomas," explains the researcher from the CIC.
This new property arises when the mutated variants of RHOA attach to a specific form of another protein, RAP1GDS1. That interaction triggers anomalously a signaling cascade characteristic of T lymphocytes that culminates in NFAT, a regulatory protein of gene expression whose activation contributes to lymphoma progression. Through genetic experiments in mice, the team verified that, by preventing that binding, one of the RHOA variants lost its ability to originate the tumor.
"The novelty is twofold: these mutant forms of RHOA acquire a function that the normal protein does not have and, in addition, can exert it without the chemical modification that normally allows it to anchor to cellular membranes," highlights Xosé R. Bustelo.
Reduced doses of tacrolimus to block the lymphoma
The study confirms that, once the tumor has been established, lymphoma cells continue to depend on this signaling pathway. To explore whether that vulnerability could be exploited therapeutically, the team turned to tacrolimus, which interferes with an essential step for NFAT activation.
In murine models, treatment with tacrolimus reduced the burden of tumor cells in six of the seven treated animals and promoted the death of these cells using only one quarter of the reference immunosuppressive dose. In addition, in the parameters analyzed, no signs of immunosuppression were detected: the therapy did not modify the expansion or viability of the non-tumor T lymphocytes evaluated, nor the cellular markers studied.
The drug also slowed the growth of cells from a patient with T-cell lymphoma and RHOA mutations transplanted into mice, reducing the presence of malignant cells in blood, spleen, and lymph nodes.
"We have not identified just one signal that accompanies cancer, but a pathway on which the lymphoma cells depend in order to keep growing. That dependency gives us a starting point for investigating new therapeutic strategies," says Javier Robles-Valero, the first author of the work together with Lucía Fernández-Nevado.
Although the results point to a possible strategy to control lymphoma without inducing generalized immunosuppression, the authors insist that this is preclinical work. They emphasize that the drug has not been administered to patients in this study, but that its action has been evaluated exclusively in mice, including models that carried transplanted patient cells. More research will be needed before determining whether this approach can be applied safely and effectively to the treatment of people with lymphomas with mutations in RHOA.
In the project, coordinated by Xosé R. Bustelo, the CIBERONC, the Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER, CSIC and Universidad de Sevilla), and Weill Cornell Medicine, in New York, have been involved. The research has been funded by the Fundación "la Caixa", the Agencia Estatal de Investigación—dependent on the Ministry of Science, Innovation and Universities—, the Junta de Castilla y León, European funds FEDER, the Científica Foundation of the Asociación Española Contra el Cáncer, and the Instituto de Salud Carlos III, among other entities.